Halozyme Posts $2.01 Q3 EPS as Royalty Engine Keeps Rolling
HALO has more than doubled off its 52-week low of $61.225.
Summary
Halozyme reported third-quarter EPS of $2.01, a fresh quarterly print with no prior guidance figure in the record to grade it against, alongside third-quarter net income of $247M and revenue of $493M. The company enters this report on a strong run: Q2 2026 revenue hit a record $481M, up 48% year over year, with royalty revenue of $308M (+50%) driven by DARZALEX SC, VYVGART Hytrulo and Phesgo. It also carries fresh firepower after closing an upsized $1.5B convertible notes offering in September and a $1B buyback authorization. The October injunction halting Merck's Keytruda SC in multiple European markets adds a potential royalty tailwind, and the company raised its full year 2026 financial guidance to total revenue of $1.860-$1.925B, royalty revenue of $1.235-$1.255B, adjusted EBITDA of $1.240-$1.290B and non-GAAP diluted EPS of $8.75-$9.05.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Halozyme raised 2026 guidance: total revenue $1.860-$1.925B, royalty revenue $1.235-$1.255B, adjusted EBITDA $1.240-$1.290B, non-GAAP diluted EPS $8.75-$9.05.
At the time of this announcement, HALO was trading at $123.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14B. The 52-week trading range was $61.23 to $134.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.